UK markets close in 6 hours 26 minutes

Medigene AG (0QGJ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.1550-0.0200 (-1.70%)
As of 09:47AM BST. Market open.
Full screen
Previous close1.1750
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume490
Avg. volume128
Market cap28.363M
Beta (5Y monthly)0.86
PE ratio (TTM)N/A
EPS (TTM)-0.4060
Earnings date15 Aug 2024 - 19 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

    Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the Chinese Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1) and LAGE 1a (L Antigen Family Member-1a), both being well-recognized and validated c

  • GlobeNewswire

    Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

    Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell (TCR-T) therapy, at the 7th Cell and Gene Therapy In-Depth Focus Summit from June 27-28, 2024, in Beijing, China. MDG1015 advances towards the

  • GlobeNewswire

    Medigene Reports Results of Annual General Meeting

    Shareholders approve all proposed resolutionsRe-election of two members of the Supervisory BoardReduction of share capital by consolidation of shares at a ratio of 2:1 approvedCreation of new authorized capital provide the Company with operational and strategic flexibility Planegg/Martinsried, June 24, 2024. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, an